Polaryx Therapeutics (PLYX) vs Rani Therapeutics (RANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Polaryx Therapeutics is the larger company by market cap ($93.7 million vs $90.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLYX | RANI |
|---|---|---|
| Share price | $1.88 | $0.6406 |
| Market cap | $93.71M | $90.02M |
| 1-day change | -3.59% | -5.79% |
| YTD return | — | -52.55% |
| 1-year return | — | -60.94% |
| 5-year return | — | -96.54% |
| EPS (TTM) | $-0.14 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.63M |
| Revenue growth (YoY) | — | +58.85% |
| Net income (latest FY) | $-8.98M | $-29.67M |
| Operating margin | — | -2345.99% |
| Net margin | — | -1817.09% |
| 52-week high | $48.91 | $3.87 |
| 52-week low | $1.85 | $0.613 |
| Distance from 52-week high | -96.16% | -83.45% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +298.94% | +1023.95% |
| Average volume | 70.79K | 720.45K |
| Shares outstanding | 49.85M | 115.42M |
| Employees | 2 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
PLYX vs RANI FAQ
Which is bigger, Polaryx Therapeutics or Rani Therapeutics?
Polaryx Therapeutics (PLYX) is larger, with a market capitalization of $93.71M compared with $90.02M for Rani Therapeutics (RANI).
Are Polaryx Therapeutics and Rani Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.